163 related articles for article (PubMed ID: 7912842)
1. The utility of large, simple trials in the evaluation of AIDS treatment strategies.
Ellenberg SS; Foulkes MA
Stat Med; 1994 Mar 15-Apr 15; 13(5-7):405-15. PubMed ID: 7912842
[No Abstract] [Full Text] [Related]
2. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
Lin DY; Fischl MA; Schoenfeld DA
Stat Med; 1993 May; 12(9):835-42. PubMed ID: 8101011
[TBL] [Abstract][Full Text] [Related]
3. Surrogate markers in AIDS and cancer trials.
Fleming TR
Stat Med; 1994 Jul 15-30; 13(13-14):1423-35; discussion 1437-40. PubMed ID: 7973222
[TBL] [Abstract][Full Text] [Related]
4. [Present and future of the antiretroviral therapy].
Martinez-Vazquez JM; Cabarcos A
An Med Interna; 1996 Jan; 13(1):1-3. PubMed ID: 8679816
[No Abstract] [Full Text] [Related]
5. Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials.
Simberkoff MS; Hartigan PM; Hamilton JD; Deykin D; Gail M; Bartlett JG; Feorino P; Redfield R; Roberts R; Collins D
Control Clin Trials; 1993 Feb; 14(1):6-18. PubMed ID: 8095008
[TBL] [Abstract][Full Text] [Related]
6. [New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)].
Töglhofer W
Wien Klin Wochenschr; 1992; 104(12):363-7. PubMed ID: 1353278
[No Abstract] [Full Text] [Related]
7. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
[TBL] [Abstract][Full Text] [Related]
8. [Antiretroviral therapy in adult HIV-infected patients].
Salzberger B; Schrappe M; Diehl V
Internist (Berl); 1994 Dec; 35(12):1095-104. PubMed ID: 7883513
[No Abstract] [Full Text] [Related]
9. [Another AIDS drug. Azidothymidine--dideoxycytidine].
Moosmann EB
Fortschr Med; 1992 Jun; 110(18):28-30. PubMed ID: 1353746
[No Abstract] [Full Text] [Related]
10. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
[TBL] [Abstract][Full Text] [Related]
11. CD4 counts as surrogate markers for progression to AIDS.
Harris PJ
Ann Intern Med; 1994 Jan; 120(1):88. PubMed ID: 7902690
[No Abstract] [Full Text] [Related]
12. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
13. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials: subgroup analyses.
Stanley KE; Fischl MA; Collier AC
Science; 1994 Aug; 265(5176):1158. PubMed ID: 7915047
[No Abstract] [Full Text] [Related]
15. Marker paths. MAP Workshop (Multi-cohort Analysis Project).
Stat Med; 1993 Nov; 12(22):2099-126. PubMed ID: 7906049
[No Abstract] [Full Text] [Related]
16. [What is the future of antiviral therapy of HIV-infected patients? Reports of results of antiretroviral therapy studies at the IX. World Congress on AIDS in Berlin].
Baumgarten R
Z Arztl Fortbild (Jena); 1993 Dec; 87(12):925-6. PubMed ID: 8147004
[No Abstract] [Full Text] [Related]
17. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
[TBL] [Abstract][Full Text] [Related]
18. [Survival of patients with zidovudine resistant HIV].
Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
Ugeskr Laeger; 1994 Jan; 156(2):185-6. PubMed ID: 7905217
[TBL] [Abstract][Full Text] [Related]
19. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
Choi S; Lagakos SW; Schooley RT; Volberding PA
Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes' intrinsic lymphoproliferative capacity in patients with AIDS treated with zidovudine.
Gerding MN; Schuurman HJ; Bast BJ; Borleffs JC
AIDS; 1989 Oct; 3(10):671-3. PubMed ID: 2574585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
